Oncology

A client sought to understand the revenue opportunity in the US and Europe for a therapy targeting hematologic malignancies, in order to optimize its clinical development plan. Health Advances uncovered the advantages and disadvantages of different development approaches, and their impact on the projected sales opportunity across several indications. The client applied our insights to make critical decisions about the clinical trial strategy for this asset.

An investment bank planned to monetize royalties on an oncology radiopharmaceutical and enlisted Health Advances support. Our team assessed key market dynamics and the drivers and barriers to radiopharmaceutical uptake. We surveyed clinicians on future utilization and developed sales forecasts across geographies. The client applied our findings to inform investment negotiations.

A medical device client sought to understand the impact of alternative data packages on market access. Health Advances executed a robust interview program across numerous stakeholders to understand how different scenarios would impact reimbursement. Our client leveraged the findings to inform key investments to support favorable coverage of the device.

A biotech company with a near-approval therapy for a hematologic malignancy sought to understand biomarker testing turnaround times to determine the value of an accelerated testing protocol. Health Advances surveyed clinicians on current turnaround times and quantified the revenue impact of shortened turnaround times. The client leveraged our insights to justify investment into an accelerated CDx protocol.

Our team was engaged by the Precision Medicine Coalition (PMC) to develop a tool by which to assess the level of precision medicine adoption among hospitals and health systems in the United States. The team considered a number of factors including types of testing offered, establishment of protocols and pathways, data collection and sharing practices, and funding for precision medicine initiatives in order to develop a robust scoring framework to evaluate organizations today and in the future. A survey of 153 lab directors and CMIOs was used to gather the required inputs and "score" each organization on their level of precision medicine adoption, and the output was published in a peer-reviewed journal.

Our team developed a global strategy to ensure that all relevant patients were appropriately tested with a companion diagnostic for a key oncology therapeutic for a large pharmaceutical company.  Through a large interview with oncologists, laboratory directors, industry experts and reimbursement experts in eight geographies, the team identified the expected clinical and logistical hurdles to using the companion diagnostic given these dynamics.  The findings were used to inform the development of solutions and tactics to address the major hurdles to testing in each geography, and determine where our client should prioritize their commercialization efforts in order to effectively and efficiently ensure that patients were appropriately receiving testing.

Our team was engaged to understand the opportunity for a self-pay genomic test that could detect recurrence in hormone-positive breast cancer patients earlier than standard of care.  Through qualitative interviews and large surveys, the team gathered feedback from clinicians and patients on the value proposition of such a test and evaluated price elasticity among potential consumers.  Our team was able to provide our client with a robust revenue forecast to assist in their decision to continue pursuing this opportunity and determine the optimal price to maximize the self-pay market at launch.

Health Advances conducted a detailed evaluation of the US market opportunity for a major NIPT laboratory for a private equity client. Our team assessed the payer coverage policies, reimbursement rates, and pricing trends for NIPT across risk segments and evaluated the increasingly complex competitive landscape in order to forecast the overall US NIPT market over 5 years, as well as the specific offerings of the Target. Based on this assessment, our team made recommendations to our private equity client on whether or not to pursue this investment, as well as outlined a strategic approach that would best position the Target for success.

A leading global pharma company with growing portfolio of immunology drugs engaged Health Advances to assess opportunities for digital biomarkers that could add value in trials or in the clinic in six disease states: Atopic Dermatitis, Psoriasis, IBD, Crohn’s Disease, Lupus and Psoriatic Arthritis. Through interviews with KOLs and industry experts and a deep review of clinical literature, the team identified potential technologies that could be used to develop digital biomarkers that address shortcomings in screening, diagnosis, treatment selection and long-term management of these conditions today. The resulting deliverable was a prioritized list of digital biomarker opportunities to consider in the near-term, including tactical considerations for successful execution and attractive partners to approach to access the required technologies for success.